Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiratricol withdrawal versus continuation in males with MCT8 deficiency
2022-001478-78Phase 3Active
- Sponsor
- Egetis Therapeutics
- Start
- Oct 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acapatamab in Allan-Herndon-Dudley syndrome (AHDS) (2 arms), sponsored by Egetis Therapeutics. Primary endpoint: Proportion meeting rescue criterion. Started Oct 2022; status: active.
02
Drugs
acapatamab
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on 2022-001478-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001478-78.